Company: INDP
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001641172-25-023333
Chunk: 40

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 1
Chunk 40
---
 the fiscal year ended December 31, 2024, as filed with
the SEC on March 13, 2025. The consolidated balance sheet data as of December 31, 2024, included in these unaudited condensed consolidated
financial statements was derived from the audited financial statements for the year ended December 31, 2024, but does not include all
disclosures required by US GAAP for annual financial statements.

The
results for the six-month period ended June 30, 2025, are not necessarily indicative of the results expected for the year ending December
31, 2025.

Principles
of consolidation

The
unaudited condensed consolidated financial statements include the accounts of Indaptus Therapeutics, Inc. and its subsidiaries. Intercompany
balances and transactions have been eliminated upon consolidation.

Use
of estimates

The
preparation of the unaudited condensed consolidated financial statements in accordance with US GAAP requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the
financial statements, and the reported amounts of expenses during the reporting periods. The most significant estimates relate to the
determination of the fair value of stock-based compensation and the determination of period-end obligations to certain contract research
organizations. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors,
including the current economic environment, and adjusts when facts and circumstances dictate. These estimates are based on information
available as of the date of the condensed consolidated financial statements; therefore, actual results could differ from those estimates.

Loss
per share

Loss
per share, basic and diluted, is computed on the basis of the net loss for the period divided by the weighted average number of shares
of common stock outstanding during the period. Diluted loss per share is based upon the weighted average number of shares of common stock
and of common stock equivalents outstanding when dilutive. Common stock equivalents include outstanding stock options and warrants which
are included under the treasury stock method when dilutive.

    F-6

The
following number of stock options and warrants were excluded from the calculation of diluted loss per share because their effect would
have been anti-dilutive for the periods presented (share data):

SCHEDULE OF ANTI-DILUTIVE SECURITIES  

    Weighted average 

    Three months ended  
    Six months ended 

    June 30  
    June 30